SCARLESS LABORATORIES INC

BEVERLY HILLS, CA · Biotech · Private

SLI-F06, a fibromodulin-based peptide therapeutic that stimulates fibroblast migration and myofibroblast differentiation to promote diabetic wound healing

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: BEVERLY HILLS, CA
Latest Form D: $150K, Apr 2011
Total capital: $14.3M

Federal grants: $13.8M; 16 awards · 2015–2024; Rank in peer group#223 of 514
Private capital raised: $550K; 2 Form D · last Apr 2011; 187 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Apr 2024Federal grantHealth and Human S · Phase II · Novel peptide for enhancing diabetic wound healing$943K
Jul 2023Federal grantHealth and Human S · Phase II · Novel peptide-impregnated hydrogel as a wound healing device$1.1M
Mar 2023Federal grantHealth and Human S · Phase II · Novel peptide for enhancing diabetic wound healing$776K
Aug 2022Federal grantHealth and Human S · Phase II · Novel peptide-impregnated hydrogel as a wound healing device$1.3M
Sep 2021Federal grantHealth and Human S · Phase II · Novel peptide for enhancing diabetic wound healing$259K
Aug 2021Federal grantHealth and Human S · Phase II · Novel peptide-impregnated hydrogel as a wound healing device$902K
Sep 2017Federal grantHealth and Human S · Phase II · Anti-scar peptide for cleft lip repair$2.8M
Apr 2011Private capital raisedForm D · SEC · 2nd filing$150K
Apr 2011Private capital raisedForm D · SEC · 1st filing$400K

Show 9 earlier federal awards

Feb 2017Federal grantHealth and Human S · Phase II · Novel peptide-coated suture for cleft lip and palate repair$544K
Aug 2016Federal grantHealth and Human S · Phase II · A novel anti-scar peptide for cutaneous wound repair$593K
Apr 2016Federal grantHealth and Human S · Phase II · Anti-scar peptide for cleft lip repair$278K
Mar 2016Federal grantHealth and Human S · Phase II · Novel peptide-coated suture for cleft lip and palate repair$860K
Feb 2016Federal grantHealth and Human S · Phase II · A novel anti-scar peptide for cutaneous wound repair$437K
Sep 2015Federal grantHealth and Human S · Phase II · A novel anti-scar peptide for cutaneous wound repair$427K
Aug 2015Federal grantHealth and Human S · Phase I · Safety and efficacy testing of novel anti-scar peptide vs corticosteroid for scar$198K
Apr 2015Federal grantHealth and Human S · Phase II · Anti-scar peptide for cleft lip repair$1.3M
Apr 2015Federal grantHealth and Human S · Phase II · Anti-scar peptide for cleft lip repair$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#223 · top 43%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Carol DanielsonResearcherExecutive OfficerLinked by $2.8M in grants as PI
Kang TingResearcherDirectorLinked by $902K in grants as PI
Chia SooExecutive Officer, DirectorNamed in SEC Form D filings
Shuai-Hung LinDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

EPOCH BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
Galera Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
REVERAGEN BIOPHARMA, INC.Similar federal contract value in Biotech · null in contracts
Nymirum, Inc.Similar federal contract value in Biotech · null in contracts
Covira SurgicalSimilar federal contract value in Biotech · null in contracts
CHEMOSEN3D INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.